|Publication number||US2356062 A|
|Publication date||Aug 15, 1944|
|Filing date||Feb 3, 1942|
|Priority date||Feb 3, 1942|
|Publication number||US 2356062 A, US 2356062A, US-A-2356062, US2356062 A, US2356062A|
|Inventors||Charles C Johnson|
|Original Assignee||Latimer Lab Inc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (24), Classifications (8)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Patented Aug. 15, 1944 THERAPEUTIC comosrrron Charles 0. JohnsomNew York, N. Y., assignor to Inc., New York, N. -Y., a
No Drawing. Application February 3, 1942,
I corporation of New Serial No.
The present invention is concerned with compositions of the type that function by the release of nascent oxygen under body heat .for sustained therapeutic action.
As conducive to a clear understanding of the invention, it is noted that while the maximum available oxygen content of ozonized olive oillor practical purposes, is but 1.3 per cent, yet it is not feasible to use that composition full strength on delicate tissues. Such composition will cause a severe and painful stinging sensation when applied to the nasal passages for instance,
unless the oxygen content is maintained at or below .5 per cent, 1. e., not more than one-third full strength. Moreover, the completely ozonized olive oil has objectionable'odors that are not easy to mask, and the attempt to mask the s to other difficulties. v
Such ozonized oilis furthermore relatively immiscible with other oils such as unozonized olive oil or mineral oil, so that dilution of 'full strength ozonized oil gives rise to mechanical difficulties, aside from the reduced therapeutic eiiectiveness of the diluted product. eign material such as solubilizing agents, in an efiort to promote the mixture of the ozoniz-ed oil .with diluent is apt to lead to other complications,
n the. other hand, where it is attempted to ozonize the olive oil to a lesser degree, within the V limits that admit of painless application to delicate tissues the critical control of such limited e leads The introduction of forembodiment, substantially pure glycerinetrioleate is ozonized by any of the conventional ozonizing processes, desirably by s'lent electric discharge. The double bondofeach of the three acid radicals which esterify the glycerol is thus ozonized,
three oxygen atoms bridging between the carbon atoms that flankthe double bond on each of the three acid radicals.
The compound, when ozonized to the maximum extent practically attainable on a commercial scale, may. contain as high as 1.85 per cent of available oxygen thus added to the molecule of glycerol trioleate, and this is fully nity per cent higher than the corresponding maximum 1. e. '1. per cent of oxygen capable of being combined with olive oil. I The efiectiveness of the composition is thus considerably greater than that of ozonized olive oil,
. as those of the nasal passages even when used sues to which it is applied, without r .addition of oxygen to the molecule-is dimcult and the stability of the product on storage is relatively low.
It is among the objects of the present invention to provide a composition with an oxygen content capable of being slowly released in nascent vform under body heat, which oxygen content shall be much higher than the maximum attainable with olive oil, and which-composition shall yet be non-irritating in its full concentration.
even'when applied to the most'delicate tissues of the human body such, for instance, as the nasal passages.
Another object is to provide a composition for the above purpose,.which is suiilciently viscous to stay in place for effective action on the organ or upon the-tissue to. which it is applied, which has no objectionableodor, and which; while it efiectively releasesnascent oxygen when applied to body tissues, will retain its effectiveness ror' all practical purposes, when sealed'in a jar or flask in storage at normal "room temperature for a period as much astwo years.
0 the ozonized glycerol trioleate even with its high apart from the vitally important. circumstance that it is non-irritating to delicate tissues such By reason of its high added oxygen ingly 'ozonized olive'oil, sothat it will more reliably' remain in situ on the organ or on the tiseadily flowing therefrom and will function for hours by the a slow release of therapeutic nascent oxygen given up bythe molecule under body heat. The composition has no objectionable odor and need therefore not be masked and the mechanical diflicul'ty of admixing essential oils therewith and the dilution-and other objections incurred by such masking are obviated.
Except for the desiredrelease of nascent oxygen there is no break-down of the molecular structure of the composition during use. No foreign matter such as ketones, aldehydes or thelike, even small proportions of which would be irritating is present or is formedin the course of theuse of thecomposition.
While the pr ce 0! such stable saturated oils in the composition as may be-miscible with the ozonized glycerlne trioleate would theoretionly do no particular harm hysiologically, lution would be incurred, .so that the available nascent oxygen is of-lowe ercentage andthe composition is accordingly less eflective, without advantages, since as above noted,
' av ble nascent oxygen content is non-irritating to delicate tissu s The relatively viscous composition constituting According to theinventiomin one. practical the medicament or the present invention will not deteriorate materially when stored in flas or jars at norma1 room temperatures.
The composition is germicidal, fungicidal and nasal and vaginal tracts, the sinuses and the like. The composition produces exceptionally meritorious results in the treatment of secondary or tertiary burns. Another application is as a vermifuge. The composition may be solidified suftory purposes, by admixing the samewith hydrogenated cotton seed oil or the like.
Esters of fatty acids with two double bonds,
tionable from this standpoint. The ozonization of oils that contain such ingredients even in small proportions, especially if they also contain oxidizable coloring and flavoring matter is not some of them tend to explode on ozonizing.
As many changes could be made in the above out. polymerization, oxidation or decomposition.
CHARLES C. JOHNSON.
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4451480 *||Apr 16, 1982||May 29, 1984||James Howard Brown||Method of treating acne using ozonized materials|
|US4591602 *||Apr 18, 1984||May 27, 1986||James H. Brown||Ozonide esters and topical compositions containing same|
|US4983637 *||Jun 8, 1989||Jan 8, 1991||Stephen Herman||Method for treating viral infection of HIV|
|US5086076 *||Oct 19, 1990||Feb 4, 1992||Stephen Herman||Antiviral pharmaceutical compositions comprising a terpene ozonide|
|US5093326 *||Jun 19, 1989||Mar 3, 1992||Stephen Herman||Repellant compositions|
|US5126376 *||Oct 19, 1990||Jun 30, 1992||Stephen Herman||Method for treating viral infection using topical administration|
|US5190977 *||Nov 21, 1991||Mar 2, 1993||Stephen Herman||Antiviral compositions|
|US5190979 *||Jun 9, 1992||Mar 2, 1993||Stephen Herman||Ozonides of terpenes and their medical uses|
|US5260342 *||Jun 18, 1992||Nov 9, 1993||Stephen Herman||Method for treating viral infection parenterally|
|US5270344 *||Feb 24, 1992||Dec 14, 1993||Stephen Herman||Method of treating a systemic disorder using trioxolane and diperoxide compounds|
|US5364879 *||Feb 14, 1994||Nov 15, 1994||Cliveden Ltd.||Medical uses of trioxolane and diperoxide compounds|
|US5785988 *||May 10, 1996||Jul 28, 1998||Fust; Charles A.||Composition for freshening nostrils and sinus cavities|
|US6344210||Feb 16, 2001||Feb 5, 2002||Charles A. Fust||Composition for freshening nostrils and sinus cavities|
|US20050084454 *||Oct 13, 2004||Apr 21, 2005||Sinofresh Healthcare, Inc.||Compositions and methods for cleaning nasal cavities|
|US20060019987 *||Jul 22, 2005||Jan 26, 2006||Fust Charles A||Methods and compositions for inhibiting, destroying, and/or inactivating viruses|
|US20100262098 *||Dec 21, 2007||Oct 14, 2010||Sca Hygiene Products Ab||Absorbent article with odour control substance|
|US20110150959 *||Oct 3, 2008||Jun 23, 2011||Sca Hygiene Products Ab||Wipe with odour control substance|
|EP2331149A1 *||Oct 3, 2008||Jun 15, 2011||Sca Hygiene Products AB||Wipe with odour control substance|
|WO1989012626A1 *||Jun 16, 1989||Dec 28, 1989||Stephen Herman||Ozonides of terpenes and their medical uses|
|WO1990014764A1 *||Jun 5, 1990||Dec 13, 1990||Stephen Herman||Method for treating viral infection|
|WO1993012654A1 *||Dec 17, 1992||Jul 8, 1993||Stephen Herman||Medical uses of trioxolane and diperoxide compounds|
|WO2003085072A1 *||Apr 2, 2003||Oct 16, 2003||Centro Nacional De Investigaciones Cientificas (Cnic)||Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes|
|WO2009082287A1 *||Dec 21, 2007||Jul 2, 2009||Sca Hgiene Products Ab||Absorbent article with odour control substane|
|WO2012168770A1||Nov 30, 2011||Dec 13, 2012||Universita' Del Salento||Process for ozonization of a vegetable oil|
|U.S. Classification||554/213, 424/76.2, 549/431|
|Cooperative Classification||A01N1/02, A01N1/0205|
|European Classification||A01N1/02, A01N1/02C|